Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23197589 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
Conditions: Central Nervous System Lymphoma;   Intraocular Lymphoma
Intervention: Drug: Intraventricular Rituximab Plus MTX

Indicates status has not been verified in more than two years